Biogen & Alkermes get NDA for MS drug
The FDA has accepted the New Drug Application (NDA) for Biogen & Alkermes’ Diroximel Fumarate in multiple sclerosis (MS).
Read More
Tag: Diroximel Fumarate
Alkermes and Biogen announce new MS drug application for FDA
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for experimental multiple sclerosis (MS) drug diroximel fumarate.
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
